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ontreal, Canada
Current available data show that about 4% to 30% of patients treated with conventional doses
of clopidogrel do not display adequate antiplatelet response. Clopidogrel resistance is a widely
used term that remains to be clearly defined. So far, it has been used to reflect failure of
clopidogrel to achieve its antiaggregatory effect. The interpatient variability in clopidogrel
response is multifactorial. It can be due to extrinsic or intrinsic mechanisms. Among extrinsic
mechanisms are the possibility of clopidogrel underdosing in patients undergoing stenting or
with acute coronary syndrome, and drug-drug interactions involving CYP3A4. Intrinsic
mechanisms include genetic polymorphisms of the P2Y12 receptor and of the CYP3As,
accrued release of adenosine diphosphate, or up-regulation of other platelet activation
pathways. Presently, there is no definite demonstration of an association between low
responsiveness to clopidogrel and thrombotic events. The optimal level of clopidogrel-
induced platelet inhibition, which will correlate quantitatively with clopidogrel’s ability to
prevent atherothrombotic events is still lacking. Furthermore, because there is no single and
validated platelet function assay to measure clopidogrel’s antiplatelet effect, it is not justified
to routinely look for clopidogrel resistance in the clinical setting. This review discusses
currently available evidence surrounding the variability in the antiplatelet response to
clopidogrel. (J Am Coll Cardiol 2005;45:1157–64) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.034Cardiology Foundation
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Glatelet activation and aggregation play an important role in
he pathogenesis of arterial thrombosis leading to acute
oronary syndromes (ACS) and in thrombotic complica-
ions during and after percutaneous coronary interventions
PCI) (1,2). When used alone, clopidogrel has been proven
ffective in preventing ischemic events in patients with
therosclerotic vascular disease (3). In combination with
spirin, clopidogrel is the gold standard for the prevention
f subacute stent thrombosis (SAT) in patients undergoing
CI and reduces major adverse cardiovascular events in
atients with non–ST-segment elevation ACS (4,5).
spirin-resistant patients may also benefit from clopidogrel
ue to their increased platelet sensitivity to adenosine
iphosphate (ADP) (6). However, clopidogrel’s antiplatelet
ffect is not uniform in all patients (7–11).
The concept of clopidogrel resistance is increasingly evoked
n the literature in light of the newly acknowledged variability
n the antiplatelet response. However, there is currently no
lear and consensual definition of what clopidogrel resistance
eans. This article discusses the magnitude and the potential
auses of low responsiveness to clopidogrel by presenting a
omprehensive review of currently available evidence.
LATELET AGGREGATION
denosine diphosphate plays an important role in platelet
ctivation and aggregation (12,13). Upon damaged or dis-
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005, accepted January 25, 2005.upted endothelium, circulating platelets adhere to the
essel wall through interactions with the subendothelium
onstituents (collagen, von Willebrand factor, and other
dhesive proteins such as fibronectin, laminin, and vitronec-
in) (13,14). After adhesion, these anchored platelets un-
ergo conformational changes through the action of several
xtrinsic activators such as collagen, thrombin, and epineph-
ine. Once activated, platelets release the contents of their
ense (platelet agonists such as ADP and serotonin) and
lpha-granules (fibrinogen, von Willebrand factor, other
dhesive proteins, proinflammatory factors, and prothrom-
otic factors), which trigger platelet-activating intracellular
ignals in surrounding platelets. Activated platelets also syn-
hesize and release thromboxane A2 in circulation. Activated
nd degranulated platelets expose glycoprotein (GP) IIb/IIIa
eceptors at their surface allowing fibrinogen binding, which
orms bridges between adjacent activated platelets causing
latelet aggregation. In addition, the release of granule con-
ents amplifies the coagulation and inflammatory processes.
DP and its receptor. Adenosine diphosphate binds to
eighboring platelets through two G-protein coupled re-
eptors (P2Y1 and P2Y12) and the cation channel-coupled
2X1 receptor (Fig. 1) (15). The activation of P2X1 receptor
ediates a rapid transient calcium ion influx in platelets but
oes not play a major role in platelet aggregation (15).
timulation of the Gq-coupled P2Y1 receptor activates
hospholipase C and induces a transient rise in cytosolic
alcium resulting in a platelet conformational change and in
eak, transient platelet aggregation (16). Activation of the
i-coupled P2Y12 receptor by ADP liberates the Gi proteinubunits Gi and , which couple to independent signaling
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Clopidogrel Resistance April 19, 2005:1157–64vents and lead to a sustained platelet aggregation (17). The
ubunit Gi decreases the platelet cyclic adenosine mono-
hosphate (cAMP) level through the inhibition of adenylyl
yclase. This decrease in cAMP production leads, in turn, to
reduction in the activation of specific protein kinases,
hich can no longer phosphorylate the vasodilator-
timulated phosphoprotein (VASP); VASP phosphoryla-
Abbreviations and Acronyms
ACS  acute coronary syndromes
ADP  adenosine diphosphate
cAMP  cyclic adenosine monophosphate
CYP450  cytochrome P450
GPIIb/IIIa  glycoprotein IIb/IIIa
PCI  percutaneous coronary intervention
PGE1  prostaglandin E1
SAT  subacute stent thrombosis
VASP  vasodilator-stimulated phosphoprotein
igure 1. Mechanism of action of clopidogrel. Clopidogrel competitively a
inds to the P2Y1 receptor to induce change in platelet shape and a weak a
eceptor liberates the Gi protein subunits Gi and . The subunit Gi lea
denosine monophosphate (cAMP) level. This inhibits the cAMP-mediated
hich is known to be closely related to the inhibition of glyprotein IIb/IIIa
PI3K), which potentiates dense- and -granule secretion. Multiple arrows
rrows indicate inhibition, whereas solid arrows represent activation. CYP450
ctivation; PLC  phospholipase C.ion is crucial for GP IIb/IIIa receptor inhibition (17). The
ubunit  activates the phosphatidylinositol 3-kinase, which
s an important signaling molecule for P2Y12-mediated
latelet-dense granule secretion and GP IIb/IIIa receptor
ctivation (18). Signaling events downstream of the P2Y12
eceptor mediate thromboxane A2 production, -granule re-
ease, and subsequent expression of P-selectin on activated
latelets (19). The P2Y12 receptor is also involved in thrombus
rowth and stability (18). Stimulation of both P2Y1 and P2Y12
eceptors is required to cause ADP-induced platelet aggrega-
ion (15). Interestingly, epinephrine, which represses cAMP
evels through its alpha2A-adrenergic receptor, can produce
ertain, but not all, features of P2Y12 signaling (18).
ECHANISM OF ACTION AND
HARMACOKINETICS OF CLOPIDOGREL
lopidogrel, an ADP-receptor antagonist, is a prodrug
equiring oxidation by the hepatic cytochrome P450
eversibly inhibits the adenosine diphosphate (ADP) P2Y12 receptor; ADP
nsient platelet aggregation. The binding of ADP to its Gi-coupled P2Y12
the inhibition of adenylyl cyclase (AC), which, in turn, lowers the cyclic
phorylation of vasodilator-stimulated phosphoprotein (VASP) (VASP-P),
tor activation. The subunit  activates the phosphatidylinositol 3-kinase
a given pathway indicate that intermediate steps may be involved. Dottednd irr
nd tra
ds to
phos
recep
within
 cytochrome P450; PGE1  prostaglandin E1; PKA  protein kinase
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April 19, 2005:1157–64 Clopidogrel ResistanceCYP450) to generate an active metabolite (20,21). Only a
mall proportion of clopidogrel undergoes metabolism by
YP450; it is mostly hydrolyzed by esterases to an inactive
arboxylic acid derivative that accounts for 85% of
lopidogrel-related circulating compounds. CYP3A4 and
YP3A5 are the enzymes responsible for the oxidation of
he thiophene ring of clopidogrel to 2-oxoclopidogrel,
hich is further oxidized, resulting in the opening of the
hiophene ring and the formation of both a carboxyl and a
hiol group (20,21). The latter forms a disulfide bridge with
he two extracellular cysteine residues located on the ADP
2Y12 receptor expressed on the platelet surface and causes
n irreversible blockade of ADP binding for the platelet’s
ife span (22).
A standard dose of clopidogrel will achieve incomplete
2Y12 antagonism, which translates into approximately 50%
nhibition of ADP-induced platelet aggregation (23). The
lopidogrel-induced platelet inhibition is dose- and time-
ependent. In healthy subjects, platelet inhibition is dose-
elated up to a single dose of 400 mg, with no further
ncrease with 600 mg (24). The maximum inhibition
btained with a single 400-mg dose is achieved after 2 to
h, whereas a daily dose of 75 mg takes 3 to 7 days to reach
he same level of inhibition (25).
In addition to its antiaggregatory effect, clopidogrel
ttenuates the increase in C-reactive protein and decreases
he expression of activated platelet-dependent inflammatory
arkers, namely CD40 ligand and CD62 P-selectin, which
ccur in patients undergoing PCI (26,27). The CD40
igand is a potent stimulus of vascular inflammation, which
romotes platelet-leukocyte interactions and induces tissue
actor expression. Clopidogrel also reduces the formation of
latelet-leukocyte conjugates in patients with non–ST-
egment elevation ACS (28).
REVALENCE AND CONTRIBUTING
ACTORS TO CLOPIDOGREL RESISTANCE
lopidogrel-induced platelet inhibition is patient-specific
7,8). The concept of clopidogrel resistance has emerged in
he medical literature to reflect the failure to inhibit platelet
unction in vitro, although its existence and definition
emain to be established. It has been proposed that the term
esistance encompasses patients for whom clopidogrel does
ot achieve its pharmacological effect, and failure of therapy
eflects patients who have recurrent events on therapy (29).
The prevalence of clopidogrel nonresponse in patients is
valuated between 4% and 30% 24 h after administration
7,8,10,30–32). The reported rates vary between studies
ecause of the technique used to measure the extent of
latelet aggregation and the presence of factors contributing
o greater baseline platelet reactivity. Furthermore, the
efinition of nonresponders is not standardized.
latelet function assays. Platelet function is measured in
itro, in most instances, by light transmission aggregometry.
lthough this method is still considered as the gold stan- iard, it carries some disadvantages such as limited repro-
ucibility and complex sample preparation (33,34). Other
echniques are available, but not all are adequate to monitor
lopidogrel antiaggregatory effect (34).
Adenosine-diphosphate-induced platelet aggregation is
idely used to measure the effect of clopidogrel, but it may
ot be the most suitable test. Although clopidogrel prevents
DP from promoting platelet aggregation via its P2Y12
eceptor, ADP can still induce a transient platelet aggrega-
ion via its P2Y1 receptor (15). Furthermore, the extent of
2Y1-dependent platelet aggregation may vary widely
mong patients taking clopidogrel. A more specific way to
ssess the antiaggregatory effect of clopidogrel would be to
easure the extent of ADP-induced inhibition of adenylyl
yclase, which is mediated uniquely by the P2Y12 receptor
35).
Also, ADP concentrations used to induce platelet aggre-
ation influence the detected rate of nonresponders, which
ill be increased with higher ADP concentrations (10).
urthermore, use of a low concentration of ADP (e.g.,
M) can only elicit the primary, and rapidly reversible,
hase of platelet aggregation, a phase that is easily inhibited
ut may not be clinically meaningful (7,30,36).
The time chosen to measure platelet aggregation is also of
aramount importance because a 300-mg loading dose of
lopidogrel can only elicit its full antiplatelet effect at 24 h in
ontrast with a 600-mg loading dose, which can achieve its
aximum effect after only 4 h (8,37,38). In one study,
oughly half of the patients who were considered nonre-
ponders at 24 h postloading of clopidogrel became re-
ponders by 30 days (9). This finding may be attributed to
he weaning of early post-stenting platelet activation as time
ccrues after the procedure.
Presently, the validity of the reported rates of clopi-
ogrel nonresponders is undermined by the absence of a
onsensual and justified platelet aggregation inhibition
utoff value to identify nonresponders to clopidogrel.
uthors have used empirically defined cutoff values
arying between 10% to 40% to segregate nonre-
ponders from responders (7,8,10,30,31).
These arbitrary cutoff values do not make sense clinically
ecause the optimal level of inhibition of platelet aggrega-
ion to prevent cardiovascular events may vary upon the
linical situation. While there is no available data on the
lopidogrel P2Y12 receptor occupancy rate, a binding study
ndicated that clopidogrel, given as 75 mg/day for 10 days in
ealthy subjects, reduced approximately by 60% the number
f binding sites for ADP (39). The remaining binding sites
hat were insensitive to clopidogrel may either be located on
he P2Y1 receptors or reflect clopidogrel’s incomplete P2Y12
eceptor occupancy. So far, no study has compared clopi-
ogrel receptor occupancy rate between nonresponsive and
esponsive patients. In a porcine model of stent thrombosis,
lopidogrel produced a dose-dependent inhibition of stent
hrombosis (40). A dose of clopidogrel producing 40%
nhibition of ADP-induced platelet aggregation reduced by
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Clopidogrel Resistance April 19, 2005:1157–646% the stent clot weight, whereas a higher dose reaching
0% platelet inhibition decreased the clot weight by 86%.
ne can speculate that, in a high-risk clinical situation, the
equired level of platelet inhibition should be higher than in
low-risk clinical situation.
ontributing factors to greater baseline platelet reactivity.
igh pretreatment platelet reactivity and thrombotic bur-
en may contribute to a lower clopidogrel antiplatelet effect
s these patients remain the most reactive during the first
ve days of clopidogrel treatment (8). Similarly, a 450-mg
lopidogrel loading dose given 3 h before PCI resulted in
lower inhibition of platelet aggregation in patients with a
igher unstable angina class on presentation as compared
ith patients having stable angina or lower unstable angina
lass (19  22% vs. 32  22%; p  0.0044) (11). Patient’s
ody mass index may be another contributing factor to the
ariability in platelet response to clopidogrel. Overweight
atients (body mass index 25 kg/m2), due in part to their
ropensity to insulin resistance, demonstrated a reduced
ntiplatelet effect with clopidogrel (31,41). However, this
ata needs to be confirmed because of the small sample size
nd nonrandomized design of the study.
A recent study in the context of elective PCI suggested
hat postclopidogrel platelet reactivity is more related to
aseline platelet reactivity than to clopidogrel responsive-
ess (42). About 16% of patients with moderate-to-high
aseline platelet reactivity remained with moderate post-
reatment reactivity despite being responsive to clopidogrel.
Considering all the factors that may affect platelet aggre-
ation, it is of paramount importance to measure baseline
alue and report percent change from baseline rather than
sing an arbitrary cutoff.
LINICAL RELEVANCE OF CLOPIDOGREL RESISTANCE
nly two small trials explored the clinical relevance of an
nadequate platelet response to clopidogrel (43,44). Their
uthors suggested that clopidogrel nonresponders may be at
igher risk for thrombotic events.
Barragan et al. (43) demonstrated that patients experi-
ncing SAT had a significantly higher platelet reactivity at
he time of intervention for stent thrombosis compared with
heir counterparts who did not have a SAT but were
eceiving similar antiplatelet pretreatment. This study, how-
ver, did not separately analyze patients taking clopidogrel
rom those taking ticlopidine. Finally, platelet aggregation
evel was not assessed at baseline for either group. Given the
igh interindividual variability in platelet reactivity and in
aboratory test responses, it is mandatory to compare the
esults obtained before and after clopidogrel administration.
therwise, this may lead to inaccurate and paradoxical
nterpretation of the findings (35).
Interestingly, Barragan et al. (43) used a flow cytometric
ssay based on the quantification of the VASP phosphory-
ation state to evaluate thienopyridine’s antiplatelet effect.
his assay exploited the rationale that the level of VASP whosphorylation is closely related to the degree of inhibition
f ADP-induced GP IIb/IIIa receptor activation and is,
herefore, more specific to clopidogrel (Fig. 1). The phos-
horylation of VASP is stimulated by the prostaglandin E1
PGE1) via the increase in platelet cAMP level. In contrast,
DP inhibits PGE1-stimulated VASP phosphorylation by
owering the cAMP level through its effects on the P2Y12
eceptor. The VASP phosphorylation flow cytometry assay
s performed by incubating blood samples in vitro with ADP
nd/or PGE1 before immunolabeling them with a monoclonal
ntibody directed against serine 239-phosphorylated VASP.
ean fluorescence intensity corresponding to each experi-
ental condition, resting (PGE1 alone) and activated plate-
ets (ADP  PGE1) is determined to establish a ratio that
irectly correlates with the VASP phosphorylation state and
s expressed as a mean percentage of platelet reactivity.
lopidogrel does not alter the basal and PGE1-stimulated
ASP phosphorylation but strongly attenuates the inhibi-
ory effect of ADP on PGE1-stimulated VASP phosphor-
lation (17). A fall in VASP phosphorylation after stimu-
ation by ADP indicates incomplete inhibition of the P2Y12
eceptor by clopidogrel.
In the second study, 60 patients with ST-segment eleva-
ion myocardial infarction undergoing primary PCI were
tratified in quartiles based on their percent inhibition of
DP-induced platelet aggregation at day 6 compared to
aseline (44). Patients in the first quartile (n  15) were
onsidered resistant to clopidogrel (ADP-induced platelet
ggregation  103  8%). Patients in the second quartile
hrough fourth quartile showed an increasing response to
lopidogrel (69  3%, 58  7%, and 33  12%, respec-
ively). Six of the 15 patients (40%) in the first quartile
eveloped a recurrent cardiovascular event (ST-segment
levation myocardial infarction, SAT, ACS, and acute
eripheral arterial occlusion) through the six-month
ollow-up period, whereas only 1 patient of 15 (6.7%) in the
econd quartile experienced an event. No recurrent cardiac
vent occurred in patients in the third and fourth quartiles.
owever, the small sample size and the low number of
ecurrent cardiovascular events made this study underpow-
red and precluded any strong conclusions.
In brief, before any definitive conclusion can be drawn
bout the clinical consequences of low antiplatelet response
o clopidogrel, these results need to be reproduced in a
arger set of patients. Inhibition of platelet aggregation
emains to be correlated efficiently with clinical outcomes.
or this to occur, the platelet function assay has to be
pecific to clopidogrel effect and give reproducible results.
f note, the standard dosing regimen of clopidogrel used
or coronary stenting was derived mainly from studies
nvolving healthy volunteers and stable patients with coro-
ary artery disease not undergoing stenting (45). The dose
f clopidogrel selected in clinical trials was equivalent to
iclopidine 250 mg twice daily in terms of platelet inhibition
nd bleeding time. However, in the context of PCI or ACS
here the thrombotic burden is heightened, the standard
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reakthrough effect.
Importantly, the relative contribution of the anti-
nflammatory properties of clopidogrel to its clinical benefit has
ot been weighted against its antiplatelet effect. In patients
onresponsive to clopidogrel, the importance of this anti-
nflammatory effect has not been assessed.
If faced with a time constraint, one approach to increase
he response to clopidogrel may be to give a higher loading
ose of clopidogrel such as 600 mg, which will provide a
aster and greater inhibition of platelet aggregation than the
tandard 300-mg loading dose (10,46). Another option
ould be to use a higher transient maintenance dose during
ritical, high-risk period (e.g., after PCI). However, despite
he improvement in clopidogrel platelet inhibitory effect,
he high loading dose does not eliminate interindividual
ariability in clopidogrel response (46). This calls for a
ontributing role of other factors beside drug dose to this
henomenon. Whether a high clopidogrel loading dose would
e of any value in patients nonresponsive to a standard dosing
egimen remains to be established.
OTENTIAL MECHANISMS
F CLOPIDOGREL RESISTANCE
everal mechanisms of clopidogrel resistance are possible
nd can be classified into two categories: extrinsic and
ntrinsic (Table 1).
Extrinsic mechanisms that reflect a reduced bioavailabil-
ty of clopidogrel may include noncompliance to clopidogrel
herapy, underdosing, or inappropriate dosing of clopi-
ogrel, and drug-drug interactions affecting the biotransfor-
ation of clopidogrel into its active metabolite (29).
Possible intrinsic mechanisms may include polymor-
hisms of the P2Y12 receptor gene leading to an increased
umber of P2Y12 receptors, and polymorphisms of the
YP3As (29). There are also possibilities of increased
elease of ADP and up-regulation of other platelet activa-
ion pathways (such as thrombin, ADP, collagen, throm-
able 1. Potential Mechanisms of Clopidogrel Resistance
Extrinsic mechanisms
1. Patient non-compliance
2. Under-dosing or inappropriate dosing of clopidogrel
3. Drug-drug interactions involving CYP3A4
Intrinsic mechanisms
1. Genetic variables
a. Polymorphisms of P2Y12 receptor
b. Polymorphisms of CYP3As
2. Increase release of ADP
3. Alternate pathways of platelet activation:
a. Failure to inhibit catecholamine-mediated platelet activation
(epinephrine)
b. Greater extent of P2Y1-dependent platelet aggregation
c. Up-regulation of P2Y12-independent pathways (thrombin,
thromboxane A2, collagen)
DP  adenosine diphosphate; CYP3As  cytochrome P450 3As.oxane A2, and epinephrine) (29). arug-drug interactions. Any medication inhibiting or
eing a substrate of the CYP3A4 can potentially block the
onversion of clopidogrel into its active metabolite. Among
hese medications figure hydroxymethylglutaryl-CoA re-
uctase inhibitors, commonly referred to as statins. Most
ommercially available statins are lipophilic, with the excep-
ion of pravastatin, and must be metabolized, usually he-
atically, to hydrophilic derivatives before they can be
xcreted through the kidney. Lovastatin and simvastatin
how moderate affinity, whereas atorvastatin demonstrates a
ower affinity to CYP3A4 (47,48). Fluvastatin and rosuva-
tatin are substrates of CYP2C9 (47).
Currently available atorvastatin is an active acid form and
weak substrate for CYP3A4. However, this acid form is
apidly converted to its lactone form by numerous enzymatic
rocesses and has a significantly higher binding affinity for
YP3A4 than the acid form (49). The interaction between
torvastatin and clopidogrel was first revealed using genet-
cally engineered microsomes of human CYP3A4 and
YP3A5 showing atorvastatin lactone greatly inhibited
90%) CYP3A4-dependent clopidogrel metabolism, more
o than the atorvastatin acid form (20).
Lau et al. (50) reiterated the relevancy of this interaction
y demonstrating that atorvastatin, at a dose of 40 mg,
roduced a dose-dependent and statistically significant re-
uction in the antiplatelet effect of clopidogrel, which
emained significant six to eight days after stent implanta-
ion. In contrast, pravastatin, a non–CYP3A4-metabolized
tatin, did not influence the level of clopidogrel-induced
latelet inhibition in patients undergoing successful PCI.
lthough interesting, the Lau et al. (50) results have been
uestioned because a nonstandard platelet function assay,
he point-of-care MICROS cell counter (ABX Diagnostics,
rvine, California) and the Plateletworks test platform
Helena Laboratories, Beaumont, Texas), were used.
Others confirmed the interaction, involving not only
torvastatin but simvastatin as well (51). They also revealed
hat the magnitude of the interaction on clopidogrel-
nduced platelet inhibition decreased over time (29% reduc-
ion in platelet inhibition with combination therapy 5 h
fter the clopidogrel loading vs. 16% by 48 h).
Since then, other investigators have refuted the relevancy
f this interaction (52–58). Retrospective analyses of data
rom the Plavix Reduction of New Thrombus Occurrence
PRONTO) trial, the Clopidogrel for the Reduction of
vents During Observation (CREDO), and the Maximal
ndividual Therapy of Acute Myocardial Infarction PLUS
MITRA PLUS) registry did not find that concomitant use
f statins compromised the antiplatelet effect of clopidogrel
ssessed both by platelet function and clinical end points
52–54). Due to their retrospective post-hoc designs, statin
dministration in these trials was not randomized, and the
oses tested were not known (52–54).
Four prospective studies, of which three were random-
zed, also evaluated the possible interaction between statins
nd clopidogrel (55–58). Two studies found that CYP3A4-
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Clopidogrel Resistance April 19, 2005:1157–64etabolized statins did not attenuate the antiplatelet effect
f clopidogrel when given as a 600-mg loading dose (55,58).
n another study, neither atorvastatin nor pravastatin sig-
ificantly affected the clopidogrel-induced platelet inhibi-
ion after five weeks of concomitant treatment (56). How-
ver, statin doses used were low and not representative of
he current practice (55,56). In the Interaction of Atorva-
tatin and Clopidogrel Study (INTERACTION), the in-
estigators performed serial measurements of 19 platelet
haracteristics using conventional aggregometry, rapid ana-
yzers, and flow cytometry to demonstrate that no signifi-
ant differences in the antiplatelet effect were seen between
oadministration of atorvastatin or other statins and clopi-
ogrel 4 and 24 h after loading with clopidogrel (57).
The divergent results observed in these studies may be
ttributed to several factors: variability in the method used to
ssess platelet function, small sample size (50–58), compari-
ons of nonequivalent statin doses (55), pooling of simvastatin
nd lovastatin data against atorvastatin (54,57), lack of baseline
ssessment of platelet aggregation before statin, and clopi-
ogrel administration (58). These methodological limitations
hus affect the interpretability of the results.
In summary, although the interaction between CYP3A4-
etabolized statins and clopidogrel is possible, there is
nsufficient convincing data to judge the clinical conse-
uences of this interaction at the present time. For now,
linicians should rely on landmark clinical trials that still
romote the concomitant use of statins and clopidogrel in
atients at high risk of coronary events (59).
enetic implications. It is estimated that genetics can
ccount for 20% to 95% of variability in drug disposition
nd efficacy (60).
OLYMORPHISMS OF THE P2Y12 RECEPTOR. Until recently,
ll the mutations described for the P2Y12 gene resulted in
ongenital bleeding disorders (18). Platelets of patients
arrying these polymorphisms retain the capacity to change
onformation when exposed to ADP, but undergo only a
light, rapidly reversible aggregation response. In most
ases, the defects in the P2Y12 gene is characterized by
ecreased ADP binding to platelets caused by one or two
ase pair deletions (each in a different location) that disrupt
eceptor synthesis (18). In one case, the ADP-mediated
ggregation and repression of PGE1-stimulated cAMP
evels by ADP is defective despite normal ADP binding to
ts P2Y12 receptor due to two missense mutations located in
egions that are important for the signal transduction
hrough the P2Y12 receptor (61).
Lately, Fontana et al. (62) found sequence variations in
he P2Y12 gene in 98 healthy volunteers taking no medica-
ion in the previous 10 days that might explain the interin-
ividual variability in ADP-induced platelet aggregation.
hree single-nucleotide polymorphisms and a single-
ucleotide insertion polymorphism in the P2Y12 gene were
iscovered. H1 was defined as the major haplotype (e.g.,
arrying none of the four polymorphisms) and H2 as the Cinor haplotype (e.g., carrying all four polymorphisms). Of
he 98 subjects, 74 carried no H2 allele (H1/H1), 21
howed one H2 allele (H1/H2), and 3 had two H2 alleles
H2/H2), resulting in frequencies of 86% and 14% for
aplotypes H1 and H2, respectively. The H2 haplotype was
ssociated with higher maximal platelet aggregation in
esponse to ADP 2 M, with median values of 34.7% in
1/H1 subjects, 67.9% in H1/H2 subjects, and 82.4% in
2/H2 subjects (p  0.0071). The authors also showed
hat, among 184 patients with known peripheral artery
isease, 30% of them had at least one H2 allele, compared
ith 21% of control subjects (odds ratio, 1.6; 95% confi-
ence interval, 1.1 to 2.5; p  0.02) (63). They did not
ention whether patients with peripheral artery disease
nrolled in the study were receiving clopidogrel or not. As
tated by the authors, this small study is at risk for
alse-positive findings.
Thus, H2 haplotype carriers may have a greater predis-
osition to atherosclerotic diseases and may not respond as
ell to clopidogrel. It was hypothesized that an increase in
he number of receptors on the platelet surface would be the
ost plausible explanation for the association between the
2 haplotype and the increased platelet responsiveness to
DP.
YP3AS POLYMORPHISMS. Recently, Lau et al. (64) reiter-
ted the contribution of CYP3A4 activity to the phenom-
non of clopidogrel resistance. A significant inverse corre-
ation was observed between platelet aggregation and
YP3A4 activity (r  0.6; p  0.003) as measured by the
rythromycin breath test in healthy volunteers. The inves-
igators also demonstrated that by enhancing the CYP3A4
ctivity with rifampin in 10 healthy volunteers, 3 initial
onresponders (platelet inhibition 10%) and one low
esponder (platelet inhibition between 10% to 29%) to
lopidogrel exhibited enhanced platelet inhibition that then
et the definition for a clopidogrel responder (platelet
nhibition 30%).
Because CYP3A4 and CYP3A5 have overlapping sub-
trate specificity, it is difficult to segregate the relative
ontributions of the two enzymes to CYP3A-mediated
etabolism (65); CYP3As expression and activity vary
mong individuals even in the absence of drug-mediated
nhibition or induction. It is estimated that most of this
ariability is caused by individual genetic makeup (66). This
nterindividual variability in CYP3As function may have a
rofound effect in the efficacy of clopidogrel but has not
een assessed in any study. Currently, more than 30
ingle-nucleotide polymorphisms of CYP3A4 have been
dentified (65). These coding variants may contribute to, but
re not likely to be, the major cause of interindividual
ifferences in CYP3A-dependent metabolism, because of
he low allele frequencies and limited alterations in enzyme
xpression or catalytic function. So far, over 10 single-
ucleotide polymorphisms have been identified in the
YP3A5 gene (67); CYP3A5*3 is the most common and
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tudied. This variant confers low CYP3A5 protein expres-
ion (67).
ONCLUSIONS
urrent available data show that about 4% to 30% of
atients treated with conventional doses of clopidogrel do
ot display adequate antiplatelet response. Clopidogrel re-
istance is a term widely used but not clearly defined. So far,
t has been used to reflect failure of clopidogrel to achieve its
latelet inhibition effect. Preliminary results seem to indi-
ate that low antiplatelet effect of clopidogrel may lead to
igher risk of developing cardiovascular events. However,
he optimal level of clopidogrel-induced platelet inhibition
hat will correlate quantitatively with clopidogrel’s ability to
revent atherothrombotic events is still lacking.
The interpatient variability in clopidogrel response is
ultifactorial. It can be due to extrinsic or intrinsic mech-
nisms such as drug-drug interactions involving CYP3A4,
r genetic polymorphisms of the P2Y12 receptor and
YP3As.
In the literature, the terms of clopidogrel resistance, non-
esponse, and low response to clopidogrel are used synony-
ously, which may confuse readers. Because the response to
lopidogrel has been mostly evaluated by platelet function
ests, these terms can be considered as interchangeable as
hey reflect failure of clopidogrel to achieve its expected
ntiplatelet effect. For clarity, we propose using the term
lopidogrel resistance.
Presently, it is impossible to predict which patient will be
esistant to clopidogrel. Furthermore, because there is cur-
ently no single and validated platelet function assay to
easure clopidogrel antiplatelet effect, it is not justified to
outinely look for clopidogrel resistance in the clinical
etting. Although, no proven therapy is currently available
o overcome low responsiveness to clopidogrel, recent clin-
cal data favor use of an increased loading dose of clopi-
ogrel in patients undergoing PCI. Factors that may mod-
late individual response to clopidogrel should be better
valuated in larger controlled clinical trials. This may also
elp tailor therapy with future antiplatelet alternatives to
spirin and clopidogrel.
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esearch Centre, Hôpital du Sacré-Coeur de Montréal, 5400,
ouin Boulevard West, Montreal, Quebec, Canada H4J 1C5.
-mail: chantal.pharand@umontreal.ca.
EFERENCES
1. Selwyn AP. Prothrombotic and antithrombotic pathways in acute
coronary syndromes. Am J Cardiol 2003;91:3H–11H.
2. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis:
evolving issues and current concepts. J Am Coll Cardiol 1996;27:494–
503.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopi-
dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet 1996;348:1329–39.4. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of random-
ized and registry comparisons of ticlopidine with clopidogrel after
stenting. J Am Coll Cardiol 2002;39:9–14.
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.
Effects of clopidogrel in addition to aspirin in patients with acute
coronary syndromes without ST-segment elevation. N Engl J Med
2001;345:494–502.
6. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro
is associated with increased platelet sensitivity to adenosine diphos-
phate. Thromb Res 2002;107:45–9.
7. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations
of platelet inhibition after loading doses of clopidogrel. J Intern Med
2002;252:233–8.
8. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for
coronary stenting: response variability, drug resistance, and the effect of
pretreatment platelet reactivity. Circulation 2003;107:2908–13.
9. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel.
Am J Cardiol 2003;91:1123–5.
0. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M.
Prevalence of clopidogrel non-responders among patients with stable
angina pectoris scheduled for elective coronary stent placement.
Thromb Haemost 2003;89:783–7.
1. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on
inhibition of platelet aggregation following clopidogrel loading in
patients undergoing coronary intervention: do we need more aggressive
dosing regimens in unstable angina? Catheter Cardiovasc Interv
2003;59:21–5.
2. Woulfe D, Yang J, Brass L. ADP and platelets: the end of the
beginning. J Clin Invest 2001;107:1503–5.
3. Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in
cardiovascular disease: an update. J Am Coll Cardiol 1989;14:813–36.
4. Schafer AI. Antiplatelet therapy. Am J Med 1996;101:199–209.
5. Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic
receptors. Curr Opin Pharmacol 2003;3:175–80.
6. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced
platelet activation. II. The P2Y1 receptor mediates ADP-induced
intracellular calcium mobilization and shape change in platelets. J Biol
Chem 1998;273:2030–4.
7. Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human
platelet P2Y(AC) ADP receptor-mediated signaling by the antiplate-
let drug clopidogrel. Arterioscler Thromb Vasc Biol 1999;19:2007–11.
8. Conley PB, Delaney SM. Scientific and therapeutic insights into the
role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol
2003;10:333–8.
9. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in
platelet activation. J Clin Invest 2004;113:340–5.
0. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed
by human cytochrome P450 3A and is inhibited by atorvastatin. Drug
Metab Dispos 2003;31:53–9.
1. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochem-
istry of the active metabolite of clopidogrel. Drug Metab Dispos
2002;30:1288–95.
2. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the
human P2Y12 receptor by thiol reagents requires interaction with both
extracellular cysteine residues, Cys17 and Cys270. Blood 2003;101:
3908–14.
3. Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R. Repeated-
dose pharmacodynamics of clopidogrel in healthy subjects. Semin
Thromb Hemost 1999;25 Suppl 2:9–14.
4. Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of
clopidogrel. Semin Thromb Hemost 1999;25 Suppl 2:3–8.
5. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R.
Clopidogrel loading dose regimens: kinetic profile of pharmacody-
namic response in healthy subjects. Semin Thromb Hemost 1999;25
Suppl 2:15–9.
6. Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreat-
ment on inflammatory marker expression in patients undergoing
percutaneous coronary intervention. Am J Cardiol 2004;93:679–84.
7. Vivekananthan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel
pretreatment on periprocedural rise in C-reactive protein after percu-
taneous coronary intervention. Am J Cardiol 2004;94:358–60.
8. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interac-
tions and thrombin receptor agonist peptide-induced platelet activa-
23
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
1164 Nguyen et al. JACC Vol. 45, No. 8, 2005
Clopidogrel Resistance April 19, 2005:1157–64tion in patients with an acute coronary syndrome. J Am Coll Cardiol
2004;43:1982–8.
9. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a
fast-moving story. Circulation 2004;109:3064–7.
0. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll
RC. Frequency of nonresponse antiplatelet activity of clopidogrel
during pretreatment for cardiac catheterization. Am J Cardiol 2004;
93:456–8.
1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggre-
gation according to body mass index in patients undergoing coronary
stenting: should clopidogrel loading-dose be weight adjusted? J Inva-
sive Cardiol 2004;16:169–74.
2. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL,
Topol EJ. Variability in platelet responsiveness to clopidogrel among
544 individuals. J Am Coll Cardiol 2005;45:246–51.
3. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of
platelet function assays. Am Heart J 1998;135:S170–8.
4. Michelson AD. Platelet function testing in cardiovascular diseases.
Circulation 2004;110:e489–93.
5. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of
drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980–7.
6. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus
Apheresis Sci 2003;28:307–17.
7. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg
clopidogrel loading doses on membrane and soluble P-selectin in
patients undergoing coronary stent implantation. Am Heart J 2002;
143:118–23.
8. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose
of clopidogrel on platelet function in patients undergoing coronary
stent placement. Heart 2001;85:92–3.
9. Mills DC, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of
ADP analogues to the receptor mediating inhibition of platelet
adenylate cyclase. Arterioscler Thromb 1992;12:430–6.
0. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin
and combined therapy in a porcine ex vivo model of high-shear
induced stent thrombosis. Eur Heart J 1998;19:1538–46.
1. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R.
Limited early antiplatelet effect of 300 mg clopidogrel in patients with
aspirin therapy undergoing percutaneous coronary interventions. Eur
Heart J 2004;25:476–83.
2. Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference
between clopidogrel responsiveness and posttreatment platelet reactiv-
ity. Thromb Res 2005;115:89–94.
3. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopy-
ridines: clinical detection of coronary stent thrombosis by monitoring
of vasodilator-stimulated phosphoprotein phosphorylation. Catheter
Cardiovasc Interv 2003;59:295–302.
4. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is
associated with increased risk of recurrent atherothrombotic events in
patients with acute myocardial infarction. Circulation 2004;109:
3171–5.
5. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance
of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:
939–43.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel
loading dose during coronary stenting: effects on drug response and
interindividual variability. Eur Heart J 2004;25:1903–10.
7. Transon C, Leemann T, Dayer P. In vitro comparative inhibition
profiles of major human drug metabolising cytochrome P450 isozymes
(CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhib-
itors. Eur J Clin Pharmacol 1996;50:209–15.
8. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug inter-
actions with HMG-CoA reductase inhibitors. Clin Pharmacokinet
2002;41:343–70.9. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first
step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reduc-
tase inhibitor atorvastatin. Drug Metab Dispos 2000;28:1369–78.
0. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the
ability of clopidogrel to inhibit platelet aggregation: a new drug-drug
interaction. Circulation 2003;107:32–7.
1. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A.
Lipophilic statins interfere with the inhibitory effects of clopidogrel on
platelet function—a flow cytometry study. Eur Heart J 2003;24:
1744–9.
2. Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR.
Statins do not affect platelet inhibition with clopidogrel during
coronary stenting. Atherosclerosis 2001;159:239–41.
3. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-
atorvastatin clinical interaction from secondary analysis of a random-
ized, placebo-controlled clopidogrel trial. Circulation 2003;108:
921–4.
4. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical
benefits of clopidogrel therapy in patients with acute coronary syn-
dromes taking atorvastatin versus other statin therapies. Am J Cardiol
2003;92:285–8.
5. Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of
statins on platelet inhibition by a high loading dose of clopidogrel.
Circulation 2003;108:2195–7.
6. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA,
Tselepis AD. Atorvastatin does not affect the antiplatelet potency of
clopidogrel when it is administered concomitantly for 5 weeks in
patients with acute coronary syndromes. Circulation 2004;109:
1335–8.
7. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction
between atorvastatin or other statins and clopidogrel: results from the
interaction study. Arch Intern Med 2004;164:2051–7.
8. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects
of a 600 mg loading dose of clopidogrel are not attenuated in patients
receiving atorvastatin or simvastatin for at least 4 weeks prior to
coronary artery stenting. Eur Heart J 2004;25:1898–902.
9. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus
moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med 2004;350:1495–504.
0. Evans WE, McLeod HL. Pharmacogenomics—drug disposition,
drug targets, and side effects. N Engl J Med 2003;348:538–49.
1. Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of
defective signal transduction in the platelet P2Y12 receptor of a
patient with congenital bleeding. Proc Natl Acad Sci USA 2003;
100:1978 – 83.
2. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-
induced platelet aggregation is associated with P2Y12 gene sequence
variations in healthy subjects. Circulation 2003;108:989–95.
3. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny
JL. P2Y12 H2 haplotype is associated with peripheral arterial disease:
a case-control study. Circulation 2003;108:2971–3.
4. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic
cytochrome P450 3A4 metabolic activity to the phenomenon of
clopidogrel resistance. Circulation 2004;109:166–71.
5. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution
to variable human CYP3A-mediated metabolism. Adv Drug Deliv
Rev 2002;54:1271–94.
6. Wojnowski L. Genetics of the variable expression of CYP3A in
humans. Ther Drug Monit 2004;26:192–9.
7. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic
variability in CYP3A5 and its possible consequences. Pharmacog-
enomics 2004;5:243–72.
